pT2K-p53DN-T2A-copGFP
(Plasmid
#109229)
-
PurposeFor Tol2 transposon-mediated stable expression of dominant negative p53 and copGFP
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 109229 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepT2K-CAGGS
- Backbone size w/o insert (bp) 8083
-
Vector typeMammalian Expression
-
Selectable markerscopGFP
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namedominant negative p53
-
SpeciesM. musculus (mouse)
-
Mutationdominant negative p53
-
Entrez GeneTrp53 (a.k.a. Tp53, bbl, bfy, bhy, p44, p53)
- Promoter CAGGS
-
Tag
/ Fusion Protein
- copGFP (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site unknown (unknown if destroyed)
- 3′ cloning site unknown (unknown if destroyed)
- 5′ sequencing primer unknown (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pT2K-p53DN-T2A-copGFP was a gift from Martine Roussel (Addgene plasmid # 109229 ; http://n2t.net/addgene:109229 ; RRID:Addgene_109229) -
For your References section:
Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. Kawauchi D, Ogg RJ, Liu L, Shih DJH, Finkelstein D, Murphy BL, Rehg JE, Korshunov A, Calabrese C, Zindy F, Phoenix T, Kawaguchi Y, Gronych J, Gilbertson RJ, Lichter P, Gajjar A, Kool M, Northcott PA, Pfister SM, Roussel MF. Oncogene. 2017 Sep 14;36(37):5231-5242. doi: 10.1038/onc.2017.110. Epub 2017 May 15. 10.1038/onc.2017.110 PubMed 28504719